NCT07422792 Anabolic Response To Intravenous Amino Acids In Chronic Intestinal Failure Patients
| NCT ID | NCT07422792 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Oncology Ljubljana |
| Condition | Chronic Intestinal Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2022-04-01 |
| Primary Completion | 2024-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2022-04-01 with a primary completion date of 2024-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to gain insight into the actual protein requirements of patients with chronic intestinal failure (CIF) receiving home parenteral nutrition, which could improve clinical management of these patients. Based on collected data on protein kinetics, the study aims to further refine and personalize nutritional mixtures in patients with CIF. Additional aims include assessment of short-chain fatty acid metabolism and evaluation of gut microbiota function in patients with CIF.
Eligibility Criteria
Inclusion Criteria: \- Patients with chronic intestinal failure (CIF) receiving home parenteral nutrition.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07422792 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Intestinal Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07422792 currently recruiting?
Yes, NCT07422792 is actively recruiting participants. Contact the research team at kkorosec@onko-i.si for enrollment information.
Where is the NCT07422792 trial being conducted?
This trial is being conducted at Ljubljana, Slovenia.
Who is sponsoring the NCT07422792 clinical trial?
NCT07422792 is sponsored by Institute of Oncology Ljubljana. The trial plans to enroll 40 participants.